Company Comparison
FibroGen vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | FibroGen | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | San Francisco, CA | South San Francisco, California |
| Founded | 1993 | 2006 |
| Status | Active | Active |
| Last Funding Stage | IPO | — |
| Total Funding | — | — |
| Valuation | — | — |
What They Build
FibroGen
Biopharmaceutical company focused on developing therapies for fibrotic diseases, anemia, and cancer through innovative drug discovery.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Sector Overlap
Both FibroGen and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
Sponsored
AArchstone
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
LP portal & reportingCapital callsPortfolio tracking$297/moNo AUM fees
Now in alpha with select funds. 14-day trial available.